USING PHARMACOGENETICS TO BETTER EVALUATE NALTREXONE FOR TREATING STIMULANT ABUSE
Sponsor: |
National Institute on Drug Abuse |
Enrolling: |
Male and Female Patients |
Study Length: |
4 Days |
Clinic Visits: |
8 |
IRB Number: |
7347 |
U.S. Govt. ID: |
NCT03226223 |
Contact: |
Freymon Perez: 6467746182 / jermaine.jones@nyspi.columbia.edu |
This study will assess the ability of the opioid antagonist, naltrexone, to block the effects of intranasal methamphetamine. This study is seeking healthy male and female users of psychostimulants like cocaine, methamphetamine between the ages of 21-50. For those who pass screening, the study consists of 4 outpatient testing sessions. Participants are compensated $125 per session.
This study is closed
Investigator
Jermaine Jones, PhD
Recent non-medical use of psychostumulant drugs (e.g., cocaine, methamphetamine) |
Yes |
No |
Not seeking treatment for substance use disorders (other than nicotine) |
Yes |
No |